Patents by Inventor Claude Sene
Claude Sene has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10111947Abstract: The present invention relates to formulation comprising (i) at least one virus-based material, (ii) at least one polymer selected in the group of polyvinylpyrrolidone and derivatives thereof, (iii) at least one sugar, (iv) at least two different amino acids, (v) at least two pharmaceutical acceptable salts, wherein at least one of said salts is a phosphate salt and, optionally (vi) a pharmaceutical acceptable buffer. Such a formulation is particularly suitable for freeze-drying. The present invention also relates to the corresponding dry product, as well as its preparation process. The present invention also relates to a reconstituted material comprising said dry product, which can be administered to a patient in need thereof. Such formulation and reconstituted material are useful as vaccines, preferably for the treatment and/or the prevention of cancers, infectious diseases and/or autoimmune disorders.Type: GrantFiled: October 2, 2013Date of Patent: October 30, 2018Assignee: Transgene S.A.Inventors: Claude Sene, Mélina Chasle
-
Patent number: 9295702Abstract: The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament.Type: GrantFiled: December 23, 2014Date of Patent: March 29, 2016Assignee: Transgene S.A.Inventors: Daniel Malarme, Yves Cordier, Claude Sene
-
Publication number: 20150250869Abstract: The present invention relates to formulation comprising (i) at least one virus-based material, (ii) at least one polymer selected in the group of polyvinylpyrrolidone and derivatives thereof, (iii) at least one sugar, (iv) at least two different amino acids, (v) at least two pharmaceutical acceptable salts, wherein at least one of said salts is a phosphate salt and, optionally (vi) a pharmaceutical acceptable buffer. Such a formulation is particularly suitable for freeze-drying. The present invention also relates to the corresponding dry product, as well as its preparation process. The present invention also relates to a reconstituted material comprising said dry product, which can be administered to a patient in need thereof. Such formulation and reconstituted material are useful as vaccines, preferably for the treatment and/or the prevention of cancers, infectious diseases and/or autoimmune disorders.Type: ApplicationFiled: October 2, 2013Publication date: September 10, 2015Inventors: Claude Sene, Mélina Chasle
-
Publication number: 20150110746Abstract: The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament.Type: ApplicationFiled: December 23, 2014Publication date: April 23, 2015Inventors: Daniel Malarme, Yves Cordier, Claude Sene
-
Patent number: 9012198Abstract: The present invention relates to a method for producing and purifying a wild type, an attenuated and/or a recombinant Orthopoxvirus. The present invention relates to a purified wild type, attenuated and/or recombinant Orthopoxvirus obtained by the method of the invention and to a pharmaceutical composition, preferably a vaccine, comprising said purified Orthopoxvirus for the treatment and/or the prevention a cancer, an infectious disease and/or an autoimmune disorder, and uses thereof. The present invention also relates to the use of an immortalized avian cell line obtained from an avian cell belonging to the Anatidae family, in particular Cairina moschata immortalized avian cell lines comprising a nucleic acid sequence coding a telomerase reverse transcriptase (TERT) and optionally an E1A nucleic acid sequence, for the production of a wild type, attenuated and/or recombinant Orthopoxvirus according to the process of the invention.Type: GrantFiled: November 12, 2013Date of Patent: April 21, 2015Assignee: Transgene S.A.Inventors: Claude Sene, Sylvie Campourcy, Yves Cordier
-
Patent number: 8945581Abstract: The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament.Type: GrantFiled: October 24, 2011Date of Patent: February 3, 2015Assignee: Transgene S.A.Inventors: Daniel Malarme, Yves Cordier, Claude Sene
-
Publication number: 20140073033Abstract: The present invention relates to a method for producing and purifying a wild type, an attenuated and/or a recombinant Orthopoxvirus.Type: ApplicationFiled: November 12, 2013Publication date: March 13, 2014Applicant: TRANSGENE S.A.Inventors: Claude SENE, Sylvie CAMPOURCY, Yves CORDIER
-
Patent number: 8609392Abstract: The present invention relates to a method for producing and purifying a wild type, an attenuated and/or a recombinant Orthopoxvirus. The present invention relates to a purified wild type, attenuated and/or recombinant Orthopoxvirus obtained by the method of the invention and to a pharmaceutical composition, preferably a vaccine, comprising said purified Orthopoxvirus for the treatment and/or the prevention a cancer, an infectious disease and/or an autoimmune disorder, and uses thereof. The present invention also relates to the use of an immortalized avian cell line obtained from an avian cell belonging to the Anatidae family, in particular Cairina moschata immortalized avian cell lines comprising a nucleic acid sequence coding a telomerase reverse transcriptase (TERT) and optionally an E1A nucleic acid sequence, for the production of a wild type, attenuated and/or recombinant Orthopoxvirus according to the process of the invention.Type: GrantFiled: May 11, 2010Date of Patent: December 17, 2013Assignee: Transgene S.A.Inventors: Claude Sene, Sylvie Campourcy, Yves Cordier
-
Patent number: 8415134Abstract: The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament.Type: GrantFiled: October 24, 2011Date of Patent: April 9, 2013Assignee: Transgene S.A.Inventors: Daniel Malarme, Yves Cordier, Claude Sene
-
Patent number: 8415133Abstract: The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament.Type: GrantFiled: October 24, 2011Date of Patent: April 9, 2013Assignee: Transgene S.A.Inventors: Daniel Malarme, Yves Cordier, Claude Sene
-
Publication number: 20130084620Abstract: The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament.Type: ApplicationFiled: October 24, 2011Publication date: April 4, 2013Applicant: TRANSGENE S.A.Inventors: Daniel MALARME, Yves CORDIER, Claude SENE
-
Publication number: 20120276614Abstract: The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament.Type: ApplicationFiled: October 24, 2011Publication date: November 1, 2012Applicant: TRANSGENE S.A.Inventors: Daniel MALARME, Yves CORDIER, Claude SENE
-
Publication number: 20120093780Abstract: The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament.Type: ApplicationFiled: October 24, 2011Publication date: April 19, 2012Applicant: TRANSGENE S.A.Inventors: Daniel MALARME, Yves Cordier, Claude Sene
-
Publication number: 20120058539Abstract: The present invention relates to a method for producing and purifying a wild type, an attenuated and/or a recombinant Orthopoxvirus. The present invention relates to a purified wild type, attenuated and/or recombinant Orthopoxvirus obtained by the method of the invention and to a pharmaceutical composition, preferably a vaccine, comprising said purified Orthopoxvirus for the treatment and/or the prevention a cancer, an infectious disease and/or an autoimmune disorder, and uses thereof. The present invention also relates to the use of an immortalized avian cell line obtained from an avian cell belonging to the Anatidae family, in particular Cairina moschata immortalized avian cell lines comprising a nucleic acid sequence coding a telomerase reverse transcriptase (TERT) and optionally an E1A nucleic acid sequence, for the production of a wild type, attenuated and/or recombinant Orthopoxvirus according to the process of the invention.Type: ApplicationFiled: May 11, 2010Publication date: March 8, 2012Applicant: TRANSGENE S.A.Inventors: Claude Sene, Sylvie Campourcy, Yves Cordier
-
Patent number: 8058049Abstract: The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament.Type: GrantFiled: June 15, 2007Date of Patent: November 15, 2011Assignee: Transgene S.A.Inventors: Daniel Malarme, Yves Cordier, Claude Sene
-
Publication number: 20100008953Abstract: The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament.Type: ApplicationFiled: June 15, 2007Publication date: January 14, 2010Inventors: Daniel Malarme, Yves Cordier, Claude Sene
-
Patent number: 6582694Abstract: A method for preparing a viral aerosol from a dilute viral suspension prepared by dissolving a virus in an aqueous solution containing 6-12 g/l of a monovalent cation salt, or 50-100 g/l of a hexose, which is then nebulized with a gas pressure of 0.5-3.5 bars or an ultrasonic frequency of 2-5 MHz. The resulting aerosol composition is also disclosed.Type: GrantFiled: November 20, 2001Date of Patent: June 24, 2003Assignee: Transgene S.A.Inventors: Claude Sene, Didier Lamy
-
Method of preserving infectious recombinant viruses, aqueous viral suspension, and use as medicament
Publication number: 20030082206Abstract: The present invention provides a novel method for preserving infectious recombinant viruses in frozen or liquid form, in which infectious viruses are preserved in an aqueous solution. The recombinant virus suspension comprises an aqueous sucrose solution at a concentration of 0.75 M or above, preferably between 0.75 M and 1.5 M, or more preferably at a concentration of 1 M. The preserved aqueous viral suspension further provides a medicament that can be used therapeutically or prophylactically for the treatment of a human or animal body by gene therapy.Type: ApplicationFiled: August 15, 2002Publication date: May 1, 2003Inventor: Claude Sene -
Patent number: 6451256Abstract: The present invention provides a novel method for preserving infectious recombinant viruses in frozen or liquid form, in which infectious viruses are preserved in an aqueous solution. The recombinant virus suspension comprises an aqueous sucrose solution at a concentration of 0.75 M or above, preferably between 0.75 M and 1.5 M, or more preferably at a concentration of 1 M. The preserved aqueous viral suspension further provides a medicament that can be used therapeutically or prophylactically for the treatment of a human or animal body by gene therapy.Type: GrantFiled: June 24, 1998Date of Patent: September 17, 2002Assignee: Transgene S.A.Inventor: Claude Sene
-
Publication number: 20020106349Abstract: A method for preparing a viral aerosol from a dilute viral suspension prepared by dissolving a virus in an aqueous solution containing 6-12 g/l of a monovalent cation salt, or 50-100 g/l of a hexose, which is then nebulised with a gas pressure of 0.5-3.5 bars or a ultrasonic frequency of 2-5 MHz. The resulting aerosol composition is also disclosed.Type: ApplicationFiled: November 20, 2001Publication date: August 8, 2002Inventors: Claude Sene, Didier Lamy